Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Siglec-G represses DAMP-mediated effects on T cells
Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy
Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy
View: Text | PDF
Research Article Immunology Transplantation

Siglec-G represses DAMP-mediated effects on T cells

  • Text
  • PDF
Abstract

The role of negative regulators or suppressors of the damage-associated molecular pattern–mediated (DAMP-mediated) stimulation of innate immune responses is being increasingly appreciated. However, the presence and function of suppressors of DAMP-mediated effects on T cells, and whether they can be targeted to mitigate T cell–dependent immunopathology remain unknown. Sialic acid–binding immunoglobulin-like lectin G (Siglec-G) is a negative regulator of DAMP-mediated responses in innate immune cells, but its T cell–autonomous role is unknown. Utilizing loss-of-function–based (genetic knockout) and gain-of-function–based (agonist) approaches, we demonstrate that in the presence of certain DAMPs, Siglec-G suppressed in vitro and in vivo T cell responses. We also demonstrate that its T cell–autonomous role is critical for modulating the severity of the T cell–mediated immunopathology, graft-versus-host disease (GVHD). Enhancing the Siglec-G signaling in donor T cells with its agonist, a CD24Fc fusion protein, ameliorated GVHD while preserving sufficient graft-versus-tumor (GVT) effects in vivo. Collectively, these data demonstrate that Siglec-G is a potentially novel negative regulator of T cell responses, which can be targeted to mitigate GVHD.

Authors

Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy

×

Figure 7

CD24Fc ameliorates nonspecific TCR responses, particularly in the case of those prestimulated with HMGB-1 in human PBMCs in vitro.

Options: View larger image (or click on image) Download as PowerPoint
CD24Fc ameliorates nonspecific TCR responses, particularly in the case o...
Human peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll and cultured on anti-CD3 mAb–precoated dishes along with anti-CD28 mAb and HMGB-1 for 48 and 72 hours. Cells were harvested and stained for human CD3 and Siglec-10. (A) Left: A representative FACS plot of Siglec-10 expression in CD3+ T cells. Right: Siglec-10 expression in naive CD3+ T cells of PBMCs (n = 7). (B) Proliferation of PBMCs incubated with anti-CD3 and anti-CD28 mAbs in the presence or absence of HMGB-1 with CD24Fc for 48 hours and analyzed for proliferation following 3H-thymidine incorporation during the last 6 hours of incubation. Paired analysis of CD24Fc treatment of human PBMCs is shown. Left: Anti–CD3/CD28 stimulation along with HMGB-1 (n = 7). Right: Pretreated with HMGB-1 and anti–CD3/CD28 stimulation (n = 6). Paired t test, *P < 0.05, **P < 0.02, ***P < 0.01, ****P < 0.002 showed significant reduction between nontreatment and CD24Fc treatment. (C) Human Siglec-10–depleted PBMCs were isolated with Ficoll and MACS and cultured on anti-CD3 mAb–precoated dishes along with anti-CD28 mAb and HMGB-1 for 48 hours and analyzed for proliferation following 3H-thymidine incorporation during the last 6 hours of incubation. Paired analysis in CD24Fc treatment of human PBMCs is shown. Left: Anti–CD3/CD28 stimulation along with HMGB-1 (n = 7). Right: Pretreated with HMGB-1 and anti–CD3/CD28 stimulation (n = 6). No Tx, no treatment.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts